TY - JOUR
T1 - Precision Medicine in Hematology 2021
T2 - Definitions, Tools, Perspectives, and Open Questions
AU - Valent, Peter
AU - Orfao, Alberto
AU - Kubicek, Stefan
AU - Staber, Philipp
AU - Haferlach, Torsten
AU - Deininger, Michael
AU - Kollmann, Karoline
AU - Lion, Thomas
AU - Virgolini, Irene
AU - Winter, Georg
AU - Hantschel, Oliver
AU - Kenner, Lukas
AU - Zuber, Johannes
AU - Grebien, Florian
AU - Moriggl, Richard
AU - Hoermann, Gregor
AU - Hermine, Olivier
AU - Andreeff, Michael
AU - Bock, Christoph
AU - Mughal, Tariq
AU - Constantinescu, Stefan N.
AU - Kralovics, Robert
AU - Sexl, Veronika
AU - Skoda, Radek
AU - Superti-Furga, Giulio
AU - Jäger, Ulrich
N1 - Publisher Copyright:
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2021/3/17
Y1 - 2021/3/17
N2 - During the past few years, our understanding of molecular mechanisms and cellular interactions relevant to malignant blood cell disorders has improved substantially. New insights include a detailed knowledge about disease-initiating exogenous factors, endogenous (genetic, somatic, epigenetic) elicitors or facilitators of disease evolution, and drug actions and interactions that underlie efficacy and adverse event profiles in defined cohorts of patients. As a result, precision medicine and personalized medicine are rapidly growing new disciplines that support the clinician in making the correct diagnosis, in predicting outcomes, and in optimally selecting patients for interventional therapies. In addition, precision medicine tools are greatly facilitating the development of new drugs, therapeutic approaches, and new multiparametric prognostic scoring models. However, although the emerging roles of precision medicine and personalized medicine in hematology and oncology are clearly visible, several questions remain. For example, it remains unknown how precision medicine tools can be implemented in healthcare systems and whether all possible approaches are also affordable. In addition, there is a need to define terminologies and to relate these to specific and context-related tools and strategies in basic and applied science. To discuss these issues, a working conference was organized in September 2019. The outcomes of this conference are summarized herein and include a proposal for definitions, terminologies, and applications of precision and personalized medicine concepts and tools in hematologic neoplasms. We also provide proposals aimed at reducing costs, thereby making these applications affordable in daily practice.
AB - During the past few years, our understanding of molecular mechanisms and cellular interactions relevant to malignant blood cell disorders has improved substantially. New insights include a detailed knowledge about disease-initiating exogenous factors, endogenous (genetic, somatic, epigenetic) elicitors or facilitators of disease evolution, and drug actions and interactions that underlie efficacy and adverse event profiles in defined cohorts of patients. As a result, precision medicine and personalized medicine are rapidly growing new disciplines that support the clinician in making the correct diagnosis, in predicting outcomes, and in optimally selecting patients for interventional therapies. In addition, precision medicine tools are greatly facilitating the development of new drugs, therapeutic approaches, and new multiparametric prognostic scoring models. However, although the emerging roles of precision medicine and personalized medicine in hematology and oncology are clearly visible, several questions remain. For example, it remains unknown how precision medicine tools can be implemented in healthcare systems and whether all possible approaches are also affordable. In addition, there is a need to define terminologies and to relate these to specific and context-related tools and strategies in basic and applied science. To discuss these issues, a working conference was organized in September 2019. The outcomes of this conference are summarized herein and include a proposal for definitions, terminologies, and applications of precision and personalized medicine concepts and tools in hematologic neoplasms. We also provide proposals aimed at reducing costs, thereby making these applications affordable in daily practice.
UR - http://www.scopus.com/inward/record.url?scp=85104145064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104145064&partnerID=8YFLogxK
U2 - 10.1097/HS9.0000000000000536
DO - 10.1097/HS9.0000000000000536
M3 - Review article
C2 - 33623882
AN - SCOPUS:85104145064
SN - 2572-9241
VL - 5
SP - E536
JO - HemaSphere
JF - HemaSphere
IS - 3
ER -